Epoetin beta

{{Short description|Recombinant erythropoietin}}

{{Drugbox

| Verifiedfields = changed

| verifiedrevid = 461094284

| pronounce = {{IPAc-en|ɛ|ˈ|p|oʊ|.|ᵻ|t|ᵻ|n}}

| tradename = Neorecormon, Betapoietin, othersCenters for Medicare and Medicaid Services: [https://www.cms.gov/Medicare/Coverage/DeterminationProcess/downloads/id245TABLES.htm Erythrocyte Stimulating Agents] {{Webarchive|url=https://web.archive.org/web/20170607154642/https://www.cms.gov/Medicare/Coverage/DeterminationProcess/downloads/id245TABLES.htm |date=2017-06-07 }}. Retrieved 15 February 2017.

| Drugs.com = {{drugs.com|international|epoetin-beta}}

| licence_EU = yes

| pregnancy_AU = B3

| pregnancy_AU_comment =

| pregnancy_category =

| routes_of_administration = Intravenous, subcutaneous

| ATC_prefix = B03

| ATC_suffix = XA01

| ATC_supplemental =

| legal_AU = S4

| legal_AU_comment = [https://www.guildlink.com.au/gc/ws/ro/pi.cfm?product=ropneore10713 Australian product information] {{Webarchive|url=https://web.archive.org/web/20230109030338/https://www.guildlink.com.au/gc/ws/ro/pi.cfm?product=ropneore10713 |date=2023-01-09 }} guildlink.com.au

| legal_BR =

| legal_BR_comment =

| legal_CA =

| legal_CA_comment =

| legal_DE =

| legal_DE_comment =

| legal_NZ =

| legal_NZ_comment =

| legal_UK =

| legal_UK_comment =

| legal_US =

| legal_US_comment =

| legal_EU = Rx-only

| legal_EU_comment = {{cite web | title=NeoRecormon EPAR | website=European Medicines Agency (EMA) | date=17 September 2018 | url=https://www.ema.europa.eu/en/medicines/human/EPAR/neorecormon | access-date=9 January 2023 | archive-date=9 January 2023 | archive-url=https://web.archive.org/web/20230109030338/https://www.ema.europa.eu/en/medicines/human/EPAR/neorecormon | url-status=live }}

| legal_UN =

| legal_UN_comment =

| legal_status = Rx-only

| bioavailability =

| protein_bound =

| metabolism =

| metabolites =

| onset =

| elimination_half-life =

| duration_of_action =

| excretion =

| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}

| ChemSpiderID = none

| CAS_number_Ref = {{cascite|changed|??}}

| CAS_number = 122312-54-3

| PubChem =

| DrugBank_Ref = {{drugbankcite|correct|drugbank}}

| DrugBank = DB00016

| UNII_Ref = {{fdacite|changed|FDA}}

| UNII = 64FS3BFH5W

| KEGG_Ref = {{keggcite|changed|kegg}}

| KEGG = D03232

| IUPAC_name =

| chemical_formula_ref =

| chemical_formula =

| C= | H= | Ag= | Al= | As= | Au= | B= | Bi= | Br= | Ca= | Cl= | Co= | F= | Fe= | Gd= | I=

| K= | Li= | Mg= | Mn= | N= | Na= | O= | P= | Pt= | S= | Sb= | Se= | Sr= | Tc= | Zn= | charge=

| molecular_weight =

| molecular_weight_comment =

| SMILES =

| StdInChI =

| StdInChI_comment =

| StdInChIKey =

| density =

| density_notes =

| melting_point =

| melting_high =

| melting_notes =

| boiling_point =

| boiling_notes =

| solubility =

| sol_units =

| specific_rotation =

}}

Epoetin beta (INN), sold under the brand name Neorecormon among others, is a synthetic, recombinant{{cite journal | vauthors = Dunn CJ, Markham A | title = Epoetin beta. A review of its pharmacological properties and clinical use in the management of anaemia associated with chronic renal failure | journal = Drugs | volume = 51 | issue = 2 | pages = 299–318 | date = February 1996 | pmid = 8808169 | doi = 10.2165/00003495-199651020-00008 | s2cid = 46985336 }} form of erythropoietin, a protein that promotes the production of red blood cells. It is an erythropoiesis-stimulating agent (ESA) that is used to treat anemia, commonly associated with chronic kidney failure and cancer chemotherapy.

It is on the World Health Organization's List of Essential Medicines.{{cite book | vauthors = ((World Health Organization)) | title = World Health Organization model list of essential medicines: 22nd list (2021) | year = 2021 | hdl = 10665/345533 | author-link = World Health Organization | publisher = World Health Organization | location = Geneva | id = WHO/MHP/HPS/EML/2021.02 | hdl-access=free }}